Compare NNI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | DYN |
|---|---|---|
| Founded | 1978 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | 2003 | 2020 |
| Metric | NNI | DYN |
|---|---|---|
| Price | $132.53 | $24.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $140.00 | $37.00 |
| AVG Volume (30 Days) | 107.1K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 134.86 | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.28 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $66.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $116.62 | $8.25 |
| 52 Week High | $144.38 | $25.00 |
| Indicator | NNI | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 74.87 |
| Support Level | $128.04 | $16.47 |
| Resistance Level | $133.36 | N/A |
| Average True Range (ATR) | 2.41 | 1.19 |
| MACD | 0.09 | 0.37 |
| Stochastic Oscillator | 57.51 | 99.07 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems, which focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Asset Generation and Management.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.